Jaguar Health (JAGX) Change in Receivables (2015 - 2026)
Jaguar Health (JAGX) reported Change in Receivables of $37000.0 for Q1 2026, up 112.17% year-over-year from $17438.8 in Q1 2025, and down 35.09% quarter-over-quarter from $57000.0 in Q4 2025.
Jaguar Health (JAGX) Change in Receivables (2015 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 12 years of Change in Receivables data on file, last reported at $37000.0 in Q1 2026.
- Change in Receivables for Q1 2026 came in at $37000.0, up 112.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $335000.0 (up 215.92% YoY), and the FY2025 annual result was -$6000.0, up 98.64% from the prior year.
- Change in Receivables eased to $37000.0 in Q1 2026 per JAGX's latest filing, from $57000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $505000.0 in Q4 2023 and troughed at -$455000.0 in Q1 2024.
- A 5-year average of -$4117.6 and a median of $19000.0 in 2023 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2023 and 2025: Change in Receivables jumped 274.07% in 2023, then plunged 442.86% in 2025.
- A 5-year view of Change in Receivables shows it stood at $135000.0 in 2022, then jumped by 274.07% to $505000.0 in 2023, then plunged by 155.45% to -$280000.0 in 2024, then jumped by 120.36% to $57000.0 in 2025, then sank by 35.09% to $37000.0 in 2026.
- Business Quant data shows JAGX's Change in Receivables at $37000.0 in Q1 2026, $57000.0 in Q4 2025, and -$76000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -4.08 Mn |
| 10 | Jaguar Health | 1.44 Mn | -10.19 Mn | 19.11 Mn | 37,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37,000.00 |
| Mar 31, 2026 | 37,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Sep 30, 2025 | -76,000.00 |
| Sep 30, 2025 | -76,000.00 |
| Jun 30, 2025 | 317,000.00 |
| Jun 30, 2025 | 317,000.00 |
| Mar 31, 2025 | -304,000.00 |
| Mar 31, 2025 | -304,000.00 |
| Dec 31, 2024 | -280,000.00 |
| Dec 31, 2024 | -280,000.00 |
| Sep 30, 2024 | -14,000.00 |
| Sep 30, 2024 | -14,000.00 |
| Jun 30, 2024 | 309,000.00 |
| Jun 30, 2024 | 309,000.00 |
| Mar 31, 2024 | -455,000.00 |
| Mar 31, 2024 | -455,000.00 |
| Dec 31, 2023 | 505,000.00 |
| Dec 31, 2023 | 505,000.00 |